MabPlex International
MabPlex International is a leading global biopharmaceutical CDMO service provider, specializing in antibody, linker-toxin, and ADC production. With innovative technology, rich experience, and a professional team, MabPlex helps clients accelerate drug development from research to commercialization, contributing to the development of China's biopharmaceutical industry and promoting human health. The company has established R&D and production bases in China and the USA, and is recognized as a high-tech enterprise and a public service platform for antibody drug R&D and industrialization in Shandong.
Industries
Nr. of Employees
large (251-1000)
Patents
Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
US-11833219-B2
View Details
Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
US-11833219-B2
View DetailsProducts
CHO serum‑free production medium (basal and feed variants)
Serum‑free media formulations for suspension CHO cell lines, provided as basal and feed variants to support cell line development, high‑density culture and high recombinant protein/antibody expression.
Linker–payload library and custom linker/payload supply
On‑hand linker–payload variants and custom synthesis services for ADC development, supplying material from milligram to multi‑gram scale to support screening and early development needs.
生物医药 CDMO 服务
烟台迈百瑞国际生物医药股份有限公司提供涵盖单抗、双抗、融合蛋白、抗体偶联药物（ADC）、重组疫苗、重组蛋白等生物药的一站式、定制化、一体化 CDMO 服务。
MaxP CHO 100 Medium
A cell culture medium showing excellent performance in expressing various therapeutic proteins across different cell lines such as CHO-K1, DG44, DXB11, and CHO-S, achieving high cell density and protein expression levels.
符合国际标准的GMP生产服务
迈百瑞生产设施、质量管理体系符合中国 NMPA、美国 FDA、欧盟 EMA 的 GMP 管理规定，可提供单抗、双抗、融合蛋白、ADC等创新生物药从IND到大规模商业化生产服务。
CDO
高质量、定制化的工艺开发服务，涵盖蛋白质工程、高效表达平台、抗体偶联药物研发以及工艺和分析方法开发。
CHO serum‑free production medium (basal and feed variants)
Serum‑free media formulations for suspension CHO cell lines, provided as basal and feed variants to support cell line development, high‑density culture and high recombinant protein/antibody expression.
Linker–payload library and custom linker/payload supply
On‑hand linker–payload variants and custom synthesis services for ADC development, supplying material from milligram to multi‑gram scale to support screening and early development needs.
生物医药 CDMO 服务
烟台迈百瑞国际生物医药股份有限公司提供涵盖单抗、双抗、融合蛋白、抗体偶联药物（ADC）、重组疫苗、重组蛋白等生物药的一站式、定制化、一体化 CDMO 服务。
MaxP CHO 100 Medium
A cell culture medium showing excellent performance in expressing various therapeutic proteins across different cell lines such as CHO-K1, DG44, DXB11, and CHO-S, achieving high cell density and protein expression levels.
符合国际标准的GMP生产服务
迈百瑞生产设施、质量管理体系符合中国 NMPA、美国 FDA、欧盟 EMA 的 GMP 管理规定，可提供单抗、双抗、融合蛋白、ADC等创新生物药从IND到大规模商业化生产服务。
CDO
高质量、定制化的工艺开发服务，涵盖蛋白质工程、高效表达平台、抗体偶联药物研发以及工艺和分析方法开发。
Services
End‑to‑end services including early discovery/CMC research, cell line development, process and analytical development, clinical sample manufacturing, regulatory filing support and commercial GMP production.
Provision of an on‑hand library of linker–payload variants for rapid ADC screening, custom design and synthetic supply from milligram through multi‑gram scale to support conjugation and early development.
Newly commissioned pre‑filled syringe production line with released clinical samples and capabilities to support PFS manufacturing alongside vial and lyophilized product formats.
On‑site analytical laboratory services covering in‑process controls, release assays, stability study design and execution (long‑term, accelerated, forced degradation) to support product release and regulatory submissions.
Consulting for CMC regulatory strategy, CTD Module 3 drafting and submission support (IND/CTA/IMPD, BLA/MAA), including meeting preparation and correspondence with regulatory authorities.
Implementation of Warehouse Management Systems with IoT integration and deployment/PQ of electronic document and training management systems to enable validated digital quality and material workflows.
End‑to‑end services including early discovery/CMC research, cell line development, process and analytical development, clinical sample manufacturing, regulatory filing support and commercial GMP production.
Provision of an on‑hand library of linker–payload variants for rapid ADC screening, custom design and synthetic supply from milligram through multi‑gram scale to support conjugation and early development.
Newly commissioned pre‑filled syringe production line with released clinical samples and capabilities to support PFS manufacturing alongside vial and lyophilized product formats.
On‑site analytical laboratory services covering in‑process controls, release assays, stability study design and execution (long‑term, accelerated, forced degradation) to support product release and regulatory submissions.
Consulting for CMC regulatory strategy, CTD Module 3 drafting and submission support (IND/CTA/IMPD, BLA/MAA), including meeting preparation and correspondence with regulatory authorities.
Implementation of Warehouse Management Systems with IoT integration and deployment/PQ of electronic document and training management systems to enable validated digital quality and material workflows.
Expertise Areas
- Biologics GMP manufacturing and commercialization
- Antibody–drug conjugate (ADC) development and manufacturing
- Cell line development and high‑titer expression platforms
- Upstream and downstream process development and scale‑up
Key Technologies
- Suspension CHO cell culture
- Scale‑up to 2000 L bioreactors
- High‑throughput clone screening and Ambr/mini‑bioreactor systems
- Automated multi‑mode chromatography
News & Updates
MabPlex was awarded the 2024 Yantai Biopharmaceutical Innovation Star Enterprise.
MabPlex's warehouse management system (WMS) has been successfully launched, enhancing supply chain management.
MabPlex held its 2024 annual summary and 2025 work deployment conference.
MabPlex was honored as a leading enterprise in biopharmaceutical innovation in Yantai for 2024.
The new WMS system improves MabPlex's supply chain efficiency and compliance.
MabPlex held its 2024 annual summary and 2025 work deployment conference.
MabPlex was awarded the 2024 Yantai Biopharmaceutical Innovation Star Enterprise.
MabPlex's warehouse management system (WMS) has been successfully launched, enhancing supply chain management.
MabPlex held its 2024 annual summary and 2025 work deployment conference.
MabPlex was honored as a leading enterprise in biopharmaceutical innovation in Yantai for 2024.
The new WMS system improves MabPlex's supply chain efficiency and compliance.
MabPlex held its 2024 annual summary and 2025 work deployment conference.